A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study

This publication has 22 references indexed in Scilit:

• A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
  New England Journal of Medicine, 1996
• Hirudin in Acute Myocardial Infarction
  Circulation, 1996
• Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial
  Journal of the American College of Cardiology, 1994
• The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
  Journal of the American College of Cardiology, 1992
• Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
  The American Journal of Cardiology, 1990
• A Comparison between Heparin and Low-Dose Aspirin as Adjunctive Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction
  New England Journal of Medicine, 1990
• Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.
  Circulation, 1990
• Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?
  Circulation, 1989